Related Experiment Video
Updated: Aug 13, 2026
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
The development of conditionally replicative adenoviruses for cancer therapy
1Department of Medicine, Gene Therapy Center, University of Alabama at Birmingham, 35294-3300, USA. david.curiel@ccc.uab.edu
Abstract:
Replicative viral agents represent a novel approach for treating neoplastic disease. Tumor cell killing by the viral agent is achieved by direct consequence of the viral replication. Relative sparing of nontumor is, however, required to provide a therapeutic index of utility for cancer treatment. To this end, an ideal viral agent would, thus, possess several logical attributes, including stability and efficiency for infection and lateral spread in vivo, a preference for replication in tumor versus nontumor cells, and the capability of avoiding early detection-and eradication-by the immune system. To date, none of the agents has exhibited optimal characteristics with regard to the aforementioned attributes. Adenovirus, however, has lent itself to a process of extensive engineering that is dealing with each and every one of the major requirements and that is realizing its clinical potential. An advanced understanding of the cancer phenotype, as well as achievements in functionally exploiting viral plasticity, predicate the design and realization of conditionally replicative adenoviral agents with improved characteristics for cancer therapy.
Insights
Engineered adenoviruses show promise for cancer therapy by selectively replicating within tumor cells, leading to their destruction while sparing healthy tissues. These novel viral agents offer improved stability and immune evasion for effective treatment.
Area of Science:
- Oncolytic virotherapy
- Viral oncology
- Gene therapy for cancer
Background:
- Replicative viral agents offer a novel strategy for cancer treatment through direct tumor cell killing.
- Achieving a therapeutic index requires viral agents that spare non-tumor cells.
- Current viral agents lack optimal characteristics for stability, tumor cell specificity, and immune system evasion.
Purpose of the Study:
- To explore the potential of engineered adenoviruses as therapeutic agents for neoplastic diseases.
- To address the limitations of existing viral agents in cancer therapy.
- To design conditionally replicative adenoviral agents with enhanced characteristics for improved cancer treatment.
Main Methods:
- Engineering adenovirus to enhance stability, in vivo infection, and lateral spread.
- Developing adenoviral agents with a preference for replication in tumor versus non-tumor cells.
- Designing adenoviruses to evade early immune system detection and eradication.
Main Results:
- Adenovirus has undergone extensive engineering to meet the requirements for an ideal oncolytic agent.
- Progress has been made in addressing viral stability, tumor cell selectivity, and immune evasion.
- Conditionally replicative adenoviral agents are being realized with improved therapeutic potential.
Conclusions:
- Engineered adenoviruses demonstrate significant potential for cancer therapy.
- Advanced understanding of cancer biology and viral plasticity enables the design of improved oncolytic agents.
- Conditionally replicative adenoviruses represent a promising advancement in cancer treatment strategies.
Related Concept Videos
01:51Mechanisms of Retrovirus-induced Cancers
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...